GHRH analog is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
BRI1-associated receptor kinase 1 (BAK1) is an LRR-RLK found in A. thaliana, which has been proposed to function as an adaptor protein that is required for the proper functioning of other RLKs. Yeast two-hybrid assays have shown that AtPEPR1 and its closest analog, AtPEPR2, interact with BAK1.
=== Japanese plan for a decisive battle === From the very start of the conflict in December 1941, the Japanese war plan had been to inflict such severe and painful losses on the US military that its public would become war weary and the American government would be convinced to sue for peace and allow Japan to keep its conquests. Admiral Isoroku Yamamoto had grown wary of this strategy, but he was killed in Operation Vengeance on 18 April 1943. The following day, Admiral Mineichi Koga succeeded Yamamoto as commander-in-chief of the Combined Fleet, and Koga wanted the Imperial Japanese Navy to engage the American fleet in the "single decisive battle" in early 1944. On 31 March 1944 Koga was killed when his aircraft, a Kawanishi H8K, flew into a typhoon and crashed. Koga's chief of staff, Vice Admiral Shigeru Fukudome, was flying in an accompanying plane and carrying the Z Plan documents, and also crashed. Fukudome survived, but the Z Plan briefcase did not sink with the destroyed aircraft and was recovered by Filipino guerillas who over the next few weeks transported the documents to General Douglas MacArthur's Military Intelligence Service (MIS) in Brisbane, Australia. MIS forwarded the translated Z Plan to Admiral Chester Nimitz in Honolulu, and the Japanese plans were quickly dispatched to the fleet commanders in the Philippine Sea in June. A new commander-in-chief of the Combined Fleet, Admiral Soemu Toyoda, was appointed, and he finalized the Japanese plans known as Plan A-Go or Operation A-Go. Operation A-Go did not change much from the Z Plan, so the U.S.
Bowfin are stalking, ambush predators that customarily move into the shallows at night to prey on fish, amphibians, and aquatic invertebrates such as crawfish, other crustaceans, mollusks, and aquatic insects. Young bowfin feed mostly on small crustaceans, while adults are mostly piscivorous, but also known to be opportunistic. Some common examples of prey include frogs, bass, other bowfin, dragonflies, sunfish, crawfish, etc. Bowfin are remarkably agile, can move quickly through the water, and have a voracious appetite. Their undulating dorsal fin propels them silently through the water while stalking their prey. The attack is straightforward and swift, with a movement that lasts about 0.075 seconds. Also, some studies indicate a capacity of the bowfin to survive without food. In 1916, a female bowfin was starved for 20 months, the longest period then known that any vertebrate had been without food. Some independent studies focus on the bowfin's ability to use organic material as a source of food and studied the structure of the gill raker. They concluded that it did not benefit from the organic material in the water because the gill rakers were short with blunt processes and a short space between them. Even bacteria could enter and exit through the gill easily. Its structure alone indicated that the Amia species do not use microorganisms as a source of food.
Sources: en.wikipedia.org
=== Pharmacodynamics === Finasteride is a 5α-reductase inhibitor. It is specifically a selective inhibitor of the type II and III isoforms of the enzyme. By inhibiting these two isozymes of 5α-reductase, finasteride reduces the formation of the potent androgen dihydrotestosterone (DHT) from its precursor testosterone in certain tissues in the body such as the prostate gland, skin, and hair follicles. As such, finasteride is a type of antiandrogen, or more specifically, an androgen synthesis inhibitor. However, some authors do not define finasteride as an "antiandrogen," a term which can refer more specifically to antagonists of the androgen receptor. Finasteride results in a decrease of circulating DHT levels by about 65–70% with an oral dosage of 5 mg/day and of DHT levels in the prostate gland by up to 80–90% with an oral dosage of 1 or 5 mg/day. In parallel, circulating levels of testosterone increase by approximately 10%, while local concentrations of testosterone in the prostate gland increase by about 7-fold and local testosterone levels in hair follicles increase by around 27–53%. An oral dosage of finasteride of only 0.2 mg/day has been found to achieve near-maximal suppression of DHT levels (68.6% for 0.2 mg/day relative to 72.2% for 5 mg/day). Finasteride does not completely suppress DHT production because it lacks significant inhibitory effects on the 5α-reductase type I isoenzyme, with more than 100-fold less inhibitory potency for type I as compared to type II (IC50Tooltip Half-maximal inhibitory concentration = 313 nM and 11 nM, respectively).
Also in 1992, the Dow Corning Corporation, a silicone products and breast implant manufacturer, announced the discontinuation of five implant-grade silicones, but would continue producing 45 other, medical-grade, silicone materials—three years later, in 1995, the Dow Corning Corporation went bankrupt when it faced large class action lawsuits claiming a variety of illnesses.
== Clinical significance == FAP expression is seen on activated stromal fibroblasts of more than 90% of all human carcinomas. Stromal fibroblasts play an important role in the development, growth and metastasis of carcinomas. Several approaches to FAP targeting in cancer diagnosis and treatment are currently being tested. In diagnostic imaging radiolabeled FAP inhibitors (FAPIs) are used as PET tracers to visualize tumors. Therapeutic approaches include the use of low molecular weight inhibitors, prodrugs activated by FAP, various anti-FAP antibodies and their conjugates, FAP-CAR T cells, and FAP vaccines. By cleaving FGF-21, FAP is also thought to play a possible role in energy metabolism. Talabostat is an inhibitor of FAP and related enzymes, for which clinical trials have been done, but further research is suspended. Sibrotuzumab is a monoclonal antibody against FAP.
Risks arising from their use should not exceed the threshold of 'maximum acceptable risks'. The new implementing regulations seek to specify this threshold." While devices for neurostimulation with an intended medical purpose require a pre-market approval, their direct-to-consumer products are only subjected to the CE marking of conformity. The EU lacks specific regulations and directives dedicated to neurotechnologies. Therefore, any physician, nurse, psychologist, occupational therapist, or specialist in neurotechnology and bioengineering may conduct neurotherapy. In the United States, the Food and Drug Administration (FDA) does not regulate neurotherapy (since it is the practice of medicine). "Licenses—such as those for physicians, registered nurses, and dentists—are typically obtained after providing evidence of education and training; some require proof of passing written and/or clinical exams. Licenses allow individuals to provide a specific set of services that are considered to be within the limits of one's field, or "scope of practice". That is, licenses, for example, for physicians and registered nurses, allow them to practice neurotherapy that is considered within their area of specialty or scope of practice.
Sources: en.wikipedia.org
== Relationship to other South Asians and West Asians == A 1985 study conducted by Roychoudhury AK and Nei M indicating the values of genetic distance showed that the Sinhalese, along with the four Indian subcontinent populations from Punjab, Gujarat, Andhra Pradesh, and Bangladesh, were closer to Afghans and Iranians than the neighboring East/Southeast Asian groups represented by the Bhutanese, Malays, Bataks in northern Sumatra, and the Chinese.
== Applications == Research into the AMP family—particularly in regards to their mechanism of action—has been ongoing for nearly 20 years. Despite sustained interest, treatments derived or utilizing AMPs have not been widely adopted for clinical use for several reasons. One, drug candidates from AMPs have a narrow window of bioavailability, because peptides are quickly broken down by proteases. Two, peptide drugs are more expensive than small molecule drugs to produce, which is problematic since peptide drugs must be given in large doses to counter rapid enzymatic breakdown. These qualities also limit routes of administration, typically to injection, infusion, or slow release therapy. Research into new and improved variations derived from cathelicidin continues.
King Crimson toured to support both albums, including double bill shows with Tool. The tour was documented on the live album Heavy ConstruKction in 2000 and the Heaven & Earth (1997–2008) box set in 2019. Led Zeppelin bassist John Paul Jones and his band supported Crimson on some live shows. On 9 November 2001, King Crimson released a limited edition live EP called Level Five, featuring three new pieces: "Dangerous Curves", "Level Five" and "Virtuous Circle", plus versions of "The ConstruKction of Light" and ProjeKct's "The Deception of the Thrush", followed by an unlisted track called "ProjeKct 12th and X" after one minute of silence. A second EP followed in October 2002, Happy with What You Have to Be Happy With. This featured eleven tracks (including a live version of "Larks' Tongues in Aspic, Part IV"). Half of the tracks were processed vocal snippets by Belew, and the songs themselves varied between Soundscapes, gamelan, heavy metal and blues. The double duo line-up released King Crimson's thirteenth album, The Power to Believe, in March 2003. Fripp described it as "the culmination of three years of Crimsonising". The album incorporated, reworked and retitled versions of "Deception of the Thrush" ("The Power to Believe III"), tracks from their previous two EPs, and an extract from a Fripp Soundscape with added instrumentation and vocals, alongside "Level Five" (the final installment of the "Larks' Tongues in Aspic" suite). The Power to Believe reached No. 162 in the UK and No. 150 in the US.
== Sources == Alhakim, Youssef (1983). Syria and the French Mandate (in Arabic). Beirut: Dar Al-Nahar. Bishour, Wadi' (1994). Syria: The Making of a State and the Birth of a Nation (in Arabic) (1st ed.). Damascus, Syria: Dar Al-Yaziji. Haddad, Ghassan Mohammed Rashad (2007). Shami Papers: Contemporary Syrian History 1946-1966 (in Arabic). Madbouly Library. ISBN 9789772086276. Archived from the original on 10 August 2020. Retrieved 9 February 2025. Torrey, Gordon (1964). Syrian Politics and the Military, 1945-1958. Ohio State University Press. Archived from the original on 10 August 2020.
== Reactions == Thionyl chloride is mainly used in the industrial production of organochlorine compounds, which are often intermediates in pharmaceuticals and agrochemicals. It usually is preferred over other reagents, such as phosphorus pentachloride, as its by-products (HCl and SO2) are gaseous, which simplifies purification of the product. Many of the products of thionyl chloride are themselves highly reactive and as such it is involved in a wide range of reactions.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.